https://replicel.com/terms-and-conditions 0.0 2022-07-27 https://replicel.com/news/replicel-provides-corporate-update 0.5 2022-11-27 https://replicel.com/news/replicel-and-university-of-victoria-collaboration-leads-to-bioengineering-innovations-funding-and-patents 0.5 2021-09-16 https://replicel.com/news/replicel-life-sciences-appoints-one-of-japan-s-foremost-regenerative-medicine-industry-business-leaders-as-strategic-advisor 0.5 2021-10-12 https://replicel.com/news/replicel-files-notice-of-arbitration-against-shiseido-company-to-resolve-its-license-agreement-dispute-regarding-its-androgenetic-alopecia-cell-therapy 0.5 2021-10-17 https://replicel.com/news/replicel-announces-dermal-injector-update 0.5 2021-10-27 https://replicel.com/terms-and-conditions 0.0 2022-05-07 https://replicel.com/news/replicel-s-clinical-advisory-team-delivers-skin-rejuvenation-clinical-study-synopsis-to-its-japanese-regulatory-and-clinical-study-management-team 0.5 2021-11-08 https://replicel.com/news/replicel-terminates-license-agreement-with-shiseido 0.5 2021-12-21 https://replicel.com/news/agm-announced-for-september-22-2023 0.5 2023-08-10 https://replicel.com/news/letter-of-intention-asset-purchase- 0.5 2024-03-18 https://replicel.com/news/replicel-closed-final-tranche-of-strategic-investment-commitment 0.5 2021-12-21 https://replicel.com/news/replicel-announces-extension-to-private-placement-1 0.5 2022-05-07 https://replicel.com/news/replicel-announces-dermaprecise-trademark-for-dermal-injector-product-line 0.5 2021-10-28 https://replicel.com/news/replicel-ships-dermaprecisetm-injector-prototypes-and-consumables-to-independent-laboratory-for-clinical-simulation-testing 0.5 2021-11-08 https://replicel.com/about/fact-sheets-1 0.0 2022-09-30 https://replicel.com/news/arbitration-decisi 0.5 2024-03-26 https://replicel.com/news/closing-of-preferred-share-conversion-and-settlement-of-dividends 0.5 2024-11-26 https://replicel.com/news/replicel-announces-secured-loan-agreement 0.5 2024-04-18 https://replicel.com/news/replicel-life-sciences-enters-into-definitive-agreements-for-sale-of-company-assets 0.5 2024-08-28 https://replicel.com/news/independent-laboratory-test-results-confirm-value-of-dermaprecisetm-injection-consistency-in-clinical-simulation-testing 0.5 2022-07-26 https://replicel.com/news/replicel-s-manufacturing-inspected-by-japan-s-pmda 0.5 2022-07-25 https://replicel.com/news/replicel-life-sciences-announces-reinstatement-of-trading-conditional-acceptance-for-proposed-transaction 0.5 2024-10-17 https://replicel.com/products/rci-02 0.5 2022-01-07 https://replicel.com/contact 0.9 2021-06-07 https://replicel.com/terms-and-conditions 0.0 2021-06-07 https://replicel.com/patients/index 0.9 2021-06-07 https://replicel.com/patients/skin-study 0.8 2021-06-07 https://replicel.com/news/replicel-announces-material-patent-milestones 0.5 2022-01-07 https://replicel.com/news/reschedule-meeting-supplemental-disclosure-for-transaction-involving-the-sale-of-assets-and-board-update 0.5 2024-12-20 https://replicel.com/partners/index 0.9 2023-03-10 https://replicel.com/about/index-2 0.5 2022-01-07 https://replicel.com/patients/tendon-study 0.8 2021-06-07 https://replicel.com/patients/clinical-trials 0.9 2021-06-07 https://replicel.com/partners/ip 0.8 2021-06-07 https://replicel.com/r-d-director-laboratory-manager-or-equivalent 0.5 2022-07-27 https://replicel.com/about/index 0.5 2022-01-07 https://replicel.com/investors/videos 0.8 2021-06-07 https://replicel.com/news/dermaprecisetm-injection-system-shown-to-produce-consistently-high-cell-count-and-viability-for-cell-therapy-injections 0.5 2022-07-30 https://replicel.com/about/media-kit 0.8 2021-06-07 https://replicel.com/about/network 0.8 2021-06-07 https://replicel.com/investors/financials 0.8 2021-06-07 https://replicel.com/investors/faq 0.7 2021-06-07 https://replicel.com/news/replicel-announces-non-brokered-private-placement 0.5 2022-03-21 https://replicel.com/news/replicel-announces-material-patent-milestones-in-key-markets 0.5 2022-07-31 https://replicel.com/news/replicel-life-sciences-announces-meeting-results 0.5 2025-01-16 https://replicel.com/news/0913693-b-c-ltd-completes-name-change 0.5 2025-03-03 https://replicel.com/about/team 0.9 2021-06-07 https://replicel.com/products/rcs-01 0.9 2019-10-01 https://replicel.com/products/rch-01 0.9 2023-11-10 https://replicel.com/products/rct-01 0.9 2019-10-01 https://replicel.com/pipeline/index 0.5 2024-09-29 https://replicel.com/news/replicel-announces-federal-grant-funding-for-collaboration-with-the-university-of-victoria-canada-copy- 0.0 2019-08-01 https://replicel.com/news/chief-scientist-dr-kevin-mcelwee-interviewed-in-barcelona-article-at-eldiariomontanes-es 0.0 2019-08-01 https://replicel.com/news/replicel-announces-details-of-its-annual-general-meeting 0.5 2020-12-01 https://replicel.com/news/further-analysis-reveals-double-digit-hair-growth-in-replicels-first-in-man-clinical-trial 0.0 2019-08-01 https://replicel.com/news/how-japan-changed-the-system- 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-appoints-head-of-clinical-and-regulatory-affairs 0.0 2019-08-01 https://replicel.com/news/replicels-chief-scientific-officer-updates-european-hair-research-society-on-replicels-ts001-2009-first-in-man-clinical-trial 0.0 2019-08-01 https://replicel.com/news/replicel-presenting-at-investmnt-investor-conference-in-minneapolis 0.0 2019-08-01 https://replicel.com/news/replicel-releases-positive-results-from-the-interim-analysis-of-data-from-its-first-in-man-ts001-2009-clinical-trial 0.0 2019-08-01 https://replicel.com/news/replicel-announces-october-presentation-and-partnering-meeting-schedule 0.0 2019-08-01 https://replicel.com/news/replicel-presenting-at-two-upcoming-investment-and-partnering-forums 0.0 2019-08-01 https://replicel.com/news/replicel-and-mainpointe-pharmaceuticals-sign-strategic-investment-and-collaboration-agreement 0.5 2021-01-24 https://replicel.com/news/ask-men-features-an-interview-with-replicel-life-sciences-ceo-david-hall 0.0 2019-08-01 https://replicel.com/news/september-11th-episode-of-the-bald-truth-featuring-replicel-life-sciences 0.0 2019-08-01 https://replicel.com/news/chief-scientist-dr-kevin-mcelwee-interviewed-in-barcelona-article-at-hazteoir-org 0.0 2019-08-01 https://replicel.com/news/replicel-announces-appointment-of-leading-sports-medicine-expert-as-orthopedics-clinical-advisor-japan- 0.5 2021-05-02 https://replicel.com/news/replicel-life-sciences-appoints-new-chief-financial-officer 0.0 2019-08-01 https://replicel.com/news/replicel-ceo-provides-updated-outlook 0.0 2019-08-01 https://replicel.com/news/replicel-ceo-provides-2018-shareholder-update 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-successfully-closes-financing 0.0 2019-08-01 https://replicel.com/news/replicel-announces-a-binding-term-sheet-for-strategic-investment-and-u-s-partnership 0.5 2020-11-10 https://replicel.com/news/replicel-closes-first-tranche-of-strategic-investment-commitment 0.5 2021-02-09 https://replicel.com/news/replicel-presents-its-technology-development-and-commercialization-plans-for-japan-at-kanagawa-regenerative-medicine-industry-conference 0.5 2021-02-17 https://replicel.com/news/replicel-closes-second-tranche-of-strategic-investment-commitment 0.5 2021-04-28 https://replicel.com/news/replicel-launches-the-next-stage-of-a-research-project-with-the-university-of-british-columbia-to-build-world-class-hair-follicle-cell-data-map 0.5 2021-06-07 https://replicel.com/news/replicel-launches-preparations-for-second-skin-rejuvenation-and-tendon-regeneration-clinical-studies 0.5 2021-05-19 https://replicel.com/news/replicel-announces-appointment-of-leading-dermatologist-in-japan-as-clinical-advisor 0.5 2021-05-31 https://replicel.com/news/replicel-launches-testing-of-dermal-injector-units 0.5 2021-05-24 https://replicel.com/news/replicel-adds-independent-director 0.5 2021-06-15 https://replicel.com/news/replicel-showcases-first-fully-functional-prototypes-of-its-next-generation-dermal-injector 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-amends-terms-of-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-announces-debt-settlement 0.0 2019-08-01 https://replicel.com/news/replicel-retains-o-m-partners-to-coordinate-north-american-focused-investor-marketing-campaign 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-closing-of-third-and-final-tranche-of-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-ceo-provides-company-outlook 0.0 2019-08-01 https://replicel.com/news/united-states-patent-issued-to-replicel-for-its-novel-dermal-injection-technologies 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-inc-announces-brokered-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-pursues-non-diluting-grant-funding-to-accelerate-value-creation-and-commercialization 0.0 2019-08-01 https://replicel.com/news/replicel-to-commence-trading-on-the-tsx-venture-exchange 0.0 2019-08-01 https://replicel.com/news/replicel-announces-conditional-approval-from-tsx-venture-exchange 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-re-pricing-of-warrants 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-closing-of-brokered-and-non-brokered-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-announces-european-patents-for-its-innovative-dermal-injector-technologies 0.0 2019-08-01 https://replicel.com/news/replicel-receives-two-important-approvals-for-dermal-rejuvenation-clinical-trial 0.0 2019-08-01 https://replicel.com/news/replicel-appoints-corporate-executive-hugh-rogers-to-its-board-of-directors 0.0 2019-08-01 https://replicel.com/news/replicel-ceo-provides-2017-forecast 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-closing-of-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-non-brokered-private-placement 0.0 2019-08-01 https://replicel.com/news/5-questions-with-david-hall 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-share-consolidation-approved 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-continues-restructuring-with-share-structure-consolidation 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-extends-warrant-expiry-dates-and-amends-warrant-exercise-price 0.0 2019-08-01 https://replicel.com/news/investor-hub-news-releases-financials-analyst-coverage-events-sedar-filings-edgar-filings-presentations-fact-sheets-corporate-governance-info-request-videos-replicel 0.0 2020-06-18 https://replicel.com/news/replicel-announces-ceo-update 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-warrant-exercise-incentive-program 0.0 2019-08-01 https://replicel.com/news/replicel-receives-european-patent-for-its-innovative-dermal-injector-technology 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-cleared-to-initiate-clinical-trial-of-rcs-01-for-dermal-rejuvenation 0.0 2019-08-01 https://replicel.com/news/replicel-reports-second-quarter-2015-financial-results 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-unveils-innovative-dermal-injector-prototype 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-selected-to-present-at-cavendish-global-health-impact-forum 0.0 2019-08-01 https://replicel.com/news/replicel-announces-2014-fourth-quarter-and-year-end-financial-results 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-receives-tsx-venture-exchange-approval-to-extend-warrant-expiry-dates 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-applies-to-extend-warrant-expiry-dates 0.0 2019-08-01 https://replicel.com/news/replicel-meets-with-japanese-pharmaceutical-and-medical-devices-agency-pmda- 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-to-present-at-11th-annual-phacilitate-cell-gene-therapy-forum-in-washington-dc 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-to-present-at-world-stem-cell-summit-2014 0.0 2019-08-01 https://replicel.com/news/replicel-announces-2014-third-quarter-financial-results 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-adds-industry-specialist-to-management-team 0.0 2019-08-01 https://replicel.com/news/replicel-retains-market-making-services 0.0 2019-08-01 https://replicel.com/news/replicel-announces-2014-second-quarter-financial-results 0.0 2019-08-01 https://replicel.com/news/replicel-appoints-brooke-hurford-as-corporate-secretary-and-director-finance 0.0 2019-08-01 https://replicel.com/news/replicel-retains-ubika-communication-for-online-capital-market-exposure 0.0 2019-08-01 https://replicel.com/news/replicel-retains-christina-cameron-as-canadian-investor-relations-consultant 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-inc-announces-closing-of-second-tranche-of-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-inc-announces-closing-of-brokered-and-non-brokered-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-brokered-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-reports-2013-annual-financial-results 0.0 2019-08-01 https://replicel.com/news/replicel-reports-third-quarter-2013-financial-results-and-provides-corporate-update 0.0 2019-08-01 https://replicel.com/news/replicel-announces-stock-option-grant 0.0 2019-08-01 https://replicel.com/news/replicel-retains-westwicke-partners-as-investor-relations-counsel 0.0 2019-08-01 https://replicel.com/news/david-kwok-is-appointed-chief-financial-officer 0.5 2023-08-17 https://replicel.com/news/replicel-announces-closing-of-private-placement 0.0 2019-08-01 https://replicel.com/news/dr-jerry-shapiro-to-present-replicel-data-to-european-academy-of-dermatology-and-venereology-in-poland 0.0 2019-08-01 https://replicel.com/news/replicel-presents-further-clinical-data-and-corporate-update-at-its-annual-general-meeting-of-shareholders 0.0 2019-08-01 https://replicel.com/news/replicel-applies-for-manufacturing-approval-for-its-collagen-and-tissue-regeneration-cell-therapies 0.5 2021-07-07 https://replicel.com/news/replicel-announces-closing-of-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-to-present-at-the-11th-annual-biopartnering-north-america-conference 0.0 2019-08-01 https://replicel.com/news/replicel-announces-re-pricing-of-warrants 0.0 2019-08-01 https://replicel.com/news/replicel-announces-adoption-of-advance-notice-bylaw-and-shareholder-rights-plan-as-well-as-transitions-in-its-board-of-directors 0.5 2020-12-13 https://replicel.com/news/replicel-ceo-provides-corporate-update 0.5 2021-02-08 https://replicel.com/news/replicel-announces-record-year-in-patents-granted 0.5 2021-05-02 https://replicel.com/news/replicel-life-sciences-enrolls-first-participant-in-phase-1-2-clinical-trial-of-rct-01-for-chronic-achilles-tendinosis 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-participation-in-23rd-world-congress-of-dermatology-vancouver-bc 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-completes-financing-with-yofoto-china-health 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-and-yofoto-china-health-obtain-all-approvals-needed-to-complete-investment 0.0 2019-08-01 https://replicel.com/news/2019-ebd-biotech-showcase 0.0 2019-08-01 https://replicel.com/news/replicel-announces-federal-grant-funding-for-collaboration-with-the-university-of-victoria-canada 0.0 2019-08-01 https://replicel.com/news/groundbreaking-biotech-company-takes-major-step-forward-with-deal-with-chinese-partner 0.0 2019-08-01 https://replicel.com/news/replicel-to-present-unique-autologous-cell-treatment-for-achilles-tendinosis-at-international-society-for-cellular-therapy-conference 0.0 2019-08-01 https://replicel.com/news/replicel-ceo-anticipating-the-approval-of-their-dermal-injector-its-impact-in-europe-and-beyond 0.0 2019-08-01 https://replicel.com/news/why-replicel-may-be-the-most-compelling-biotech-company-to-watch-in-canada 0.0 2019-08-01 https://replicel.com/news/collaboration-meetings-with-yofoto-participation-in-the-yofoto-2018-global-business-seminar 0.0 2019-08-01 https://replicel.com/news/2018-gcff-shenzhen-investing-in-north-american-innovation-conference 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-signed-licensing-and-co-development-deal-for-greater-china 0.0 2019-08-01 https://replicel.com/news/injured-athletes-could-get-back-in-the-game-putting-new-cells-to-work-on-old-injuries 0.0 2019-08-01 https://replicel.com/news/impact-magazine-aching-achilles- 0.0 2019-08-01 https://replicel.com/news/partnership-greenlighted-for-canadian-biotech-and-chinese-health-products-firm 0.0 2019-08-01 https://replicel.com/news/the-province-ubc-achilles-research-could-be-key-to-revolutionary-treatment 0.0 2019-08-01 https://replicel.com/news/stockhouse-tech-roundup-replicel-v-rp-grows-somedia-v-vid-profits-wilan-wiln-flounders 0.0 2019-08-01 https://replicel.com/news/is-the-age-old-quest-for-a-baldness-cure-reaching-its-end- 0.0 2019-08-01 https://replicel.com/news/replicel-announces-completion-of-first-injections-in-clinical-trial-of-rcs-01-for-skin-aging-and-uv-damaged-skin 0.0 2019-08-01 https://replicel.com/news/2018-ebd-biotech-showcase 0.0 2019-08-01 https://replicel.com/news/japan-is-fertile-ground-for-biotech-deal 0.0 2019-08-01 https://replicel.com/news/japan-s-take-on-regenerative-medicine-early-commercialization-early-reimbursement 0.0 2019-08-01 https://replicel.com/news/replicel-s-regenerative-technology-could-take-the-polar-silk-road-to-china 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-now-finalizing-its-strategic-investment-partnership-with-china-based-yofoto 0.0 2019-08-01 https://replicel.com/news/canadian-technology-and-innovation-making-strides-in-the-global-cell-therapy-landscape 0.0 2019-08-01 https://replicel.com/news/9-challenges-keeping-cell-and-gene-therapy-executives-up-at-night 0.0 2019-08-01 https://replicel.com/news/2017-ebd-biotech-showcase 0.0 2019-08-01 https://replicel.com/news/regenerative-medicine-company-s-china-deal-is-dramatically-transformational- 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-lands-commitment-for-key-investment-partnership 0.0 2019-08-01 https://replicel.com/news/from-stem-cells-to-revenue-bringing-regenerative-medicine-to-the-masses 0.0 2019-08-01 https://replicel.com/news/company-uses-patients-own-cells-to-put-an-end-to-baldness-aging-skin-and-tendon-degeneration 0.0 2019-08-01 https://replicel.com/news/regenerative-medicine-interview-with-a-game-changing-leader 0.0 2019-08-01 https://replicel.com/news/replicel-s-partnership-initiatives-mature-into-licensing-negotiations 0.0 2019-08-01 https://replicel.com/news/your-hair-follicles-may-hold-the-key-to-younger-looking-skin 0.0 2019-08-01 https://replicel.com/news/analyst-says-cell-therapy-company-s-move-decreases-risk 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-joins-medcision-s-thawstar-early-adopter-program 0.0 2019-08-01 https://replicel.com/news/canada-s-emerging-cell-therapy-biotech-industry 0.0 2019-08-01 https://replicel.com/news/prominent-skin-aging-researcher-provides-insights-into-replicel-s-clinical-data 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-to-present-at-biotech-showcase-2015 0.0 2019-08-01 https://replicel.com/news/skin-in-the-game 0.0 2019-08-01 https://replicel.com/news/replicel-poised-to-partner-up-for-precision-control-dermal-injector 0.0 2019-08-01 https://replicel.com/news/hair-raising-r-d-replicel-developing-autologous-cell-therapy-for-baldness 0.0 2019-08-01 https://replicel.com/news/poised-for-success-with-positive-clinical-results 0.0 2019-08-01 https://replicel.com/news/a-new-approach-to-treating-hair-loss 0.0 2019-08-01 https://replicel.com/news/your-hair-could-hold-the-secret-to-mending-your-injured-tendon 0.0 2019-08-01 https://replicel.com/news/the-latest-in-biocellular-regeneration 0.0 2019-08-01 https://replicel.com/news/replicel-collaborates-with-university-of-british-columbia-to-build-world-class-hair-follicle-cell-data-map 0.0 2019-08-01 https://replicel.com/news/pioneer-in-both-biotech-business-left-noteworthy-legacy 0.0 2019-08-01 https://replicel.com/news/exclusive-interview-with-replicel-life-sciences-president-and-ceo-lee-buckler 0.0 2019-08-01 https://replicel.com/news/how-to-grow-a-regenerative-medicine-industry-in-canada-michael-may-of-ccrm 0.0 2019-08-01 https://replicel.com/news/replicel-provides-update-on-shiseido-license-and-co-development-for-rch-01 0.0 2019-08-01 https://replicel.com/news/promise-of-regenerative-medicine-already-upon-us 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-gets-price-target-raise-at-echelon-wealth-partners 0.0 2019-08-01 https://replicel.com/news/cell-therapy-scientific-breakthrough-treats-signs-of-ageing 0.0 2019-08-01 https://replicel.com/news/replicel-cell-therapy-companies-ready-to-give-you-athletic-immortality 0.0 2019-08-01 https://replicel.com/news/replicel-developing-autologous-cell-therapies-for-skin-hair-and-tendon-regeneration 0.0 2019-08-01 https://replicel.com/news/string-of-positive-trial-results-boosts-replicel-s-profile 0.0 2019-08-01 https://replicel.com/news/replicel-stem-cell-therapies-using-your-own-cells 0.0 2019-08-01 https://replicel.com/news/safety-and-efficacy-of-rct-01-in-men-and-women-with-unilateral-chronic-achilles-tendinosis-react- 0.0 2019-08-01 https://replicel.com/news/positive-results-from-replicel-s-rcs-01-phase-i-skin-trial-are-the-company-s-most-compelling-to-date 0.0 2019-08-01 https://replicel.com/news/replicel-s-successful-rct-01-tendon-repair-clinical-trial-shows-signs-of-healing-chronic-tendon-problems 0.0 2019-08-01 https://replicel.com/news/replicel-s-phase-1-clinical-trial-for-hair-loss-succeeds-in-meeting-primary-endpoints 0.0 2019-08-01 https://replicel.com/news/replicel-signs-two-key-service-partnerships-for-final-prototype-manufacturing-and-testing-of-its-dermal-injector 0.0 2019-08-01 https://replicel.com/news/podcast-replicel-life-sciences-ceo-lee-buckler-on-global-expansion 0.0 2019-08-01 https://replicel.com/news/companies-flocking-to-japan-for-biotech-deals 0.0 2019-08-01 https://replicel.com/news/espn-with-bill-daughtry 0.0 2019-08-01 https://replicel.com/news/replicel-rp-v-should-benefit-from-renewed-investor-focus-sweeping-legislation-on-cell-therapy 0.0 2019-08-01 https://replicel.com/news/will-2017-be-the-year-of-cell-therapies- 0.0 2019-08-01 https://replicel.com/news/emerging-biotech-companies-at-cantech-2017 0.0 2019-08-01 https://replicel.com/news/replicel-using-cells-for-healing 0.0 2019-08-01 https://replicel.com/news/replicel-ceo-lee-buckler-talks-to-cantech-letter 0.0 2019-08-01 https://replicel.com/news/the-jake-brown-show 0.0 2019-08-01 https://replicel.com/news/replicel-selected-as-one-of-this-year-s-top-20-public-canadian-technology-companies 0.0 2019-08-01 https://replicel.com/news/total-tutor-with-neil-haley 0.0 2019-08-01 https://replicel.com/news/japan-s-gambit-for-cell-therapy-clinical-trials 0.0 2019-08-01 https://replicel.com/news/replicel-s-cell-therapy-for-pattern-baldness-proceeds-to-clinical-trial-launch-in-japan 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-conducts-formal-consultation-review-with-japan-s-pmda-and-receives-unprecedented-review-fee-reduction 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-finishes-enrolment-for-its-tendon-repair-and-skin-rejuvenation-clinical-trials 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-applies-to-amend-warrant-exercise-price-and-extend-warrant-expiry-dates 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-restructuring-cost-reductions-and-closing-of-private-placement 0.0 2019-08-01 https://replicel.com/news/shiseido-to-trial-baldness-cure-for-planned-commercial-launch-in-2018 0.0 2019-08-01 https://replicel.com/news/embrace-low-cap-biotech-for-high-gains-eden-rahim-of-next-edge-capital 0.0 2019-08-01 https://replicel.com/news/2016-ebd-biotech-showcase 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-inc-announces-closing-of-second-tranche-of-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-leadership-transition 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-inc-announces-closing-of-first-tranche-of-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-executives-to-present-at-9th-world-congress-for-hair-research-in-miami 0.0 2019-08-01 https://replicel.com/news/first-participants-enrolled-in-replicel-s-phase-1-clinical-trial-of-its-rcs-01-dermatology-injectable 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-inc-announces-brokered-private-placement 0.0 2019-08-01 https://replicel.com/news/industry-leader-geoff-mackay-joins-replicel-life-sciences-board-of-directors 0.0 2019-08-01 https://replicel.com/news/japan-s-regulatory-gamble-and-what-it-means-for-the-industry 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-initiation-of-clinical-site-and-participant-recruitment-for-european-skin-aging-study 0.0 2019-08-01 https://replicel.com/news/alan-leong-of-biowatch-looks-beyond-the-buzz-for-solid-early-stage-plays-rp-capr-ctrv-cpxx-srne-snss 0.0 2019-08-01 https://replicel.com/news/harness-biotech-volatility-with-an-options-strategy-theta-strategy-capital-s-eden-rahim 0.0 2020-05-26 https://replicel.com/news/regenerative-medicine-in-japan-cj-partners-colin-lee-novick 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-receives-approval-to-conduct-clinical-trial-for-patients-with-chronic-achilles-tendinosis 0.0 2019-08-01 https://replicel.com/news/the-life-sciences-report-will-stem-cell-profits-measure-up- 0.0 2019-08-01 https://replicel.com/news/stockhouse-replicel-hits-lucrative-bio-med-trifecta-with-innovative-tech 0.0 2019-08-01 https://replicel.com/news/the-province-four-biotech-companies-that-are-helping-b-c-lead-the-battle-against-aging 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-in-japan-for-key-industry-meetings 0.0 2019-08-01 https://replicel.com/news/financial-post-seeking-to-cure-the-incurable 0.0 2019-08-01 https://replicel.com/news/november-7-2014-r-lee-buckler-how-replicel-is-harnessing-the-awesome-power-of-cell-therapy 0.0 2019-08-01 https://replicel.com/news/streetwise-report-interviews-biowatch-news-founder-alan-leong 0.0 2019-08-01 https://replicel.com/news/replicel-submits-clinical-trial-application-for-its-dermatological-clinical-trial 0.0 2019-08-01 https://replicel.com/news/replicel-to-present-commercial-and-clinical-update-at-biojapan-2014-world-business-forum 0.0 2019-08-01 https://replicel.com/news/the-total-tutor-interviews-ceo-david-hall-on-blogtalkradio 0.0 2019-08-01 https://replicel.com/news/houston-style-magazine-interviews-replicel-ceo 0.0 2019-08-01 https://replicel.com/news/ceo-david-hall-interviewed-on-espn-new-york-radio 0.0 2019-08-01 https://replicel.com/news/newly-released-peer-reviewed-publication-further-validates-replicels-use-of-dermal-sheath-cup-cells-to-treat-pattern-baldness 0.0 2019-08-01 https://replicel.com/news/replicel-to-present-at-rodman-renshaw-s-16th-annual-global-investment-conference-in-new-york 0.0 2019-08-01 https://replicel.com/news/vp-lee-buckler-podcast-interview-by-midas-letter 0.0 2019-08-01 https://replicel.com/news/chronic-achilles-tendinosis-video-launched 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-receives-health-canada-clearance-for-clinical-trial-in-patients-with-chronic-achilles-tendinosis 0.0 2019-08-01 https://replicel.com/news/replicel-submits-clinical-trial-application-to-health-canada-for-its-chronic-achilles-tendinosis-trial 0.0 2019-08-01 https://replicel.com/news/midas-letter-interviews-ceo-david-hall 0.0 2019-08-01 https://replicel.com/news/japan-gives-a-hug-to-the-cell-therapy-industry-r-lee-buckler 0.0 2019-08-01 https://replicel.com/news/seeking-alpha-why-replicel-is-a-promising-under-researched-small-cap-biotech 0.0 2019-08-01 https://replicel.com/news/replicel-to-present-clinical-trial-update-at-stem-cell-meeting-on-the-mesa-partnering-forum-in-california 0.0 2019-08-01 https://replicel.com/news/seeking-alpha-article-replicel-offers-significant-upside 0.0 2019-08-01 https://replicel.com/news/september-9th-2014-replicel-marches-ahead-with-cell-therapy-trials 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-inc-tsxv-rp-seeks-to-heal-with-patients-own-cells 0.0 2019-08-01 https://replicel.com/news/september-9th-2014-featured-in-the-financial-post-new-technology-puts-your-own-cells-to-work-to-repair-and-rejuvenate-your-body 0.0 2019-08-01 https://replicel.com/news/replicel-garners-feature-on-fox-business-news-and-the-financial-post 0.0 2019-08-01 https://replicel.com/news/biowatch-news-replicel-as-a-featured-company-in-june-s-issue-exploring-alopecia-and-its-industry 0.0 2019-08-01 https://replicel.com/news/july-10-2014-alan-leong-from-biowatch-news-comments-on-replicel-in-july-s-issues-of-the-life-sciences-report 0.0 2019-08-01 https://replicel.com/news/cell-therapy-group-interview-with-ceo-david-hall 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-licensing-partner-shiseido-opens-cell-processing-and-expansion-facility-in-japan-to-advance-rch-01-a-treatment-for-pattern-baldness 0.0 2019-08-01 https://replicel.com/news/replicel-to-present-rch-01-phase-1-clinical-data-at-the-13th-congress-of-the-japanese-society-for-regenerative-medicine 0.0 2019-08-01 https://replicel.com/news/vancouver-hair-loss-biotech-wins-japanese-patent 0.0 2019-08-01 https://replicel.com/news/replicel-receives-japanese-patent-covering-its-hair-regeneration-technology 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-to-present-at-biotech-showcase-2014 0.0 2019-08-01 https://replicel.com/news/a-cure-for-baldness-stem-cell-researchers-race-to-regenerate-follicles-from-hair-resistant-to-loss 0.0 2019-08-01 https://replicel.com/news/replicel-forms-clinical-advisory-board-to-support-the-development-of-rct-01-for-the-treatment-of-chronic-tendinosis 0.0 2019-08-01 https://replicel.com/news/stem-cell-technology-used-in-search-for-the-holy-grail-of-hair-treatments-a-cure-for-baldness 0.0 2019-08-01 https://replicel.com/news/replicel-and-shiseido-complete-collaboration-and-technology-transfer-agreement-on-technology-for-treating-pattern-baldness 0.0 2019-08-01 https://replicel.com/news/replicel-and-shiseido-announce-collaboration-and-technology-transfer-framework-agreement-and-exclusive-geographic-technology-license 0.0 2019-08-01 https://replicel.com/news/replicel-announces-closing-of-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-announces-new-tendon-repair-technology-based-on-its-hair-follicle-cellular-expertise 0.0 2019-08-01 https://replicel.com/news/replicel-to-meet-with-german-competent-authority-on-its-rch-01-autologous-hair-cell-manufacturing-process 0.0 2019-08-01 https://replicel.com/news/replicel-completes-first-pre-filing-review-with-german-competent-authority-on-its-rch-01-autologous-hair-cell-manufacturing-pro 0.0 2019-08-01 https://replicel.com/news/replicel-s-common-shares-listed-on-cnsx 0.0 2019-08-01 https://replicel.com/news/replicel-s-chief-medical-officer-to-present-at-21st-european-academy-of-dermatology-venereology-congress 0.0 2019-08-01 https://replicel.com/news/replicel-to-present-at-rodman-and-renshaw-global-investment-conference 0.0 2019-08-01 https://replicel.com/news/notice-of-meeting-and-record-date-nov-dec-2024 0.5 2024-12-03 https://replicel.com/news/information-circular-for-agm-and-special-meeting-2024 0.5 2024-12-20 https://replicel.com/news/preferred-share-conversion 0.5 2024-11-15 https://replicel.com/news/replicel-announces-closing-of-non-brokered-private-placement 0.5 2023-04-26 https://replicel.com/ 1.0 2023-09-20 https://replicel.com/news/replicel-files-information-circular-for-agm-and-special-shareholders-meeting-and-encourages-shareholders-to-access-meeting-materials-online 0.5 2024-12-04 https://replicel.com/news/replicel-adds-an-additional-director 0.5 2023-08-10 https://replicel.com/investors/index 0.5 2025-03-10 https://replicel.com/news/agm-slides 0.5 2025-02-21 https://replicel.com/news/shareholders-that-have-questions-are-encouraged-to-contact-andrew-schutte-at-info-replicel-com-or-call-604-248-8730 0.5 2024-12-05 https://replicel.com/news/replicel-life-sciences-announces-closing-of-asset-sale-and-royalty-transaction-and-date-for-voluntary-delisting-from-the-tsx-venture-exchange 0.5 2025-02-14 https://replicel.com/investors/corporate-governance 0.8 2023-09-22 https://replicel.com/about/fact-sheets 0.9 2022-09-30 https://replicel.com/news/replicel-announces-dermaprecise-development-milestone-updates-arbitration-proceedings 0.5 2023-09-14 https://replicel.com/news 0.0 2021-06-07 https://replicel.com/googleaf6e612d440bea6a 0.0 2021-06-07 https://replicel.com/patients/hair-study 0.8 2021-06-07 https://replicel.com/investors/publications 0.8 2021-06-07 https://replicel.com/news/replicel-life-sciences-inc-announces-closing-of-brokered-and-non-brokered-private-placement 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-announces-brokered-private-placement 0.0 2019-08-01 https://replicel.com/news/cell-therapy-is-hair-raising-in-a-good-way 0.0 2019-08-01 https://replicel.com/news/replicel-life-sciences-joins-centre-for-commercialization-of-regenerative-medicine-industry-consortium 0.0 2019-08-01 https://replicel.com/news/august-7-2014-mark-landy-from-summer-street-research-partners-comments-on-replicel-in-august-s-issues-of-the-life-sciences-report 0.0 2019-08-01 https://replicel.com/news/replicel-reports-progress-on-shiseido-technology-transfer-for-rch-01-treatment-for-pattern-baldness 0.0 2019-08-01 https://replicel.com/news/vancouver-biotech-receives-u-s-patent-for-hair-regeneration-technology 0.0 2019-08-01 https://replicel.com/news/replicel-receives-issue-notification-from-the-united-states-patent-and-trademark-office-protecting-methods-of-preparing-dermal-sheath-cup-cells-for-its-hair-regeneration-technology 0.0 2019-08-01